289 related articles for article (PubMed ID: 35945593)
1. Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels.
Álvarez-Córdoba M; Reche-López D; Cilleros-Holgado P; Talaverón-Rey M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Suárez-Carrillo A; Munuera-Cabeza M; Piñero-Pérez R; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2022 Aug; 17(1):311. PubMed ID: 35945593
[TBL] [Abstract][Full Text] [Related]
2. Down regulation of the expression of mitochondrial phosphopantetheinyl-proteins in pantothenate kinase-associated neurodegeneration: pathophysiological consequences and therapeutic perspectives.
Álvarez-Córdoba M; Talaverón-Rey M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Suárez-Carrillo A; Munuera-Cabeza M; Salas JJ; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2021 May; 16(1):201. PubMed ID: 33952316
[TBL] [Abstract][Full Text] [Related]
3. Alpha-lipoic acid supplementation corrects pathological alterations in cellular models of pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels.
Talaverón-Rey M; Álvarez-Córdoba M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Gómez-Fernández D; Romero-González A; Suárez-Carrillo A; Munuera-Cabeza M; Cilleros-Holgado P; Reche-López D; Piñero-Pérez R; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2023 Apr; 18(1):80. PubMed ID: 37046296
[TBL] [Abstract][Full Text] [Related]
4. Pantothenate Rescues Iron Accumulation in Pantothenate Kinase-Associated Neurodegeneration Depending on the Type of Mutation.
Álvarez-Córdoba M; Fernández Khoury A; Villanueva-Paz M; Gómez-Navarro C; Villalón-García I; Suárez-Rivero JM; Povea-Cabello S; de la Mata M; Cotán D; Talaverón-Rey M; Pérez-Pulido AJ; Salas JJ; Pérez-Villegas EM; Díaz-Quintana A; Armengol JA; Sánchez-Alcázar JA
Mol Neurobiol; 2019 May; 56(5):3638-3656. PubMed ID: 30173408
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration.
Álvarez-Córdoba M; Talaverón-Rey M; Povea-Cabello S; Cilleros-Holgado P; Gómez-Fernández D; Piñero-Pérez R; Reche-López D; Munuera-Cabeza M; Suárez-Carrillo A; Romero-González A; Romero-Domínguez JM; López-Cabrera A; Armengol JÁ; Sánchez-Alcázar JA
Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895830
[TBL] [Abstract][Full Text] [Related]
6. A Potential Citrate Shunt in Erythrocytes of PKAN Patients Caused by Mutations in Pantothenate Kinase 2.
Werning M; Dobretzberger V; Brenner M; Müllner EW; Mlynek G; Djinovic-Carugo K; Baron DM; Fragner L; Bischoff AT; Büchner B; Klopstock T; Weckwerth W; Salzer U
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204826
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of Novel Therapies for Pantothenate Kinase-Associated Neurodegeneration.
Thakur N; Klopstock T; Jackowski S; Kuscer E; Tricta F; Videnovic A; Jinnah HA
Mov Disord; 2021 Sep; 36(9):2005-2016. PubMed ID: 34002881
[TBL] [Abstract][Full Text] [Related]
8. Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated Neurodegeneration.
Subramanian C; Frank MW; Sukhun R; Henry CE; Wade A; Harden ME; Rao S; Tangallapally R; Yun MK; White SW; Lee RE; Sinha U; Rock CO; Jackowski S
J Pharmacol Exp Ther; 2024 Jan; 388(1):171-180. PubMed ID: 37875310
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine in pantothenate kinase-associated neurodegeneration.
Alvarez-Cordoba M; Villanueva-Paz M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Talaverón-Rey M; Abril-Jaramillo J; Vintimilla-Tosi AB; Sánchez-Alcázar JA
Neural Regen Res; 2019 Jul; 14(7):1177-1185. PubMed ID: 30804242
[TBL] [Abstract][Full Text] [Related]
10. Exploring Yeast as a Study Model of Pantothenate Kinase-Associated Neurodegeneration and for the Identification of Therapeutic Compounds.
Ceccatelli Berti C; Gilea AI; De Gregorio MA; Goffrini P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396642
[TBL] [Abstract][Full Text] [Related]
11. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model.
Brunetti D; Dusi S; Giordano C; Lamperti C; Morbin M; Fugnanesi V; Marchet S; Fagiolari G; Sibon O; Moggio M; d'Amati G; Tiranti V
Brain; 2014 Jan; 137(Pt 1):57-68. PubMed ID: 24316510
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name.
Hayflick SJ
Curr Opin Pediatr; 2003 Dec; 15(6):572-7. PubMed ID: 14631201
[TBL] [Abstract][Full Text] [Related]
13. Knock-down of pantothenate kinase 2 severely affects the development of the nervous and vascular system in zebrafish, providing new insights into PKAN disease.
Zizioli D; Tiso N; Guglielmi A; Saraceno C; Busolin G; Giuliani R; Khatri D; Monti E; Borsani G; Argenton F; Finazzi D
Neurobiol Dis; 2016 Jan; 85():35-48. PubMed ID: 26476142
[TBL] [Abstract][Full Text] [Related]
14. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2.
Kotzbauer PT; Truax AC; Trojanowski JQ; Lee VM
J Neurosci; 2005 Jan; 25(3):689-98. PubMed ID: 15659606
[TBL] [Abstract][Full Text] [Related]
15. Novel homozygous PANK2 mutation causing atypical pantothenate kinase-associated neurodegeneration (PKAN) in a Cypriot family.
Tanteles GA; Spanou-Aristidou E; Antoniou C; Christophidou-Anastasiadou V; Kleopa KA
J Neurol Sci; 2014 May; 340(1-2):233-6. PubMed ID: 24655737
[TBL] [Abstract][Full Text] [Related]
16. Neurodegeneration with brain iron accumulation.
Gregory A; Hayflick SJ
Folia Neuropathol; 2005; 43(4):286-96. PubMed ID: 16416393
[TBL] [Abstract][Full Text] [Related]
17. Atypical pantothenate kinase-associated neurodegeneration with PANK2 mutations : clinical description and a review of the literature.
Pan S; Zhu C
Neurocase; 2020 Jun; 26(3):175-182. PubMed ID: 32310012
[TBL] [Abstract][Full Text] [Related]
18. PKAN neurodegeneration and residual PANK2 activities in patient erythrocytes.
Werning M; Müllner EW; Mlynek G; Dobretzberger V; Djinovic-Carugo K; Baron DM; Prokisch H; Büchner B; Klopstock T; Salzer U
Ann Clin Transl Neurol; 2020 Aug; 7(8):1340-1351. PubMed ID: 32705819
[TBL] [Abstract][Full Text] [Related]
19. 4'-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN.
Jeong SY; Hogarth P; Placzek A; Gregory AM; Fox R; Zhen D; Hamada J; van der Zwaag M; Lambrechts R; Jin H; Nilsen A; Cobb J; Pham T; Gray N; Ralle M; Duffy M; Schwanemann L; Rai P; Freed A; Wakeman K; Woltjer RL; Sibon OC; Hayflick SJ
EMBO Mol Med; 2019 Dec; 11(12):e10489. PubMed ID: 31660701
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration.
Johnson MA; Kuo YM; Westaway SK; Parker SM; Ching KH; Gitschier J; Hayflick SJ
Ann N Y Acad Sci; 2004 Mar; 1012():282-98. PubMed ID: 15105273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
